As a simple and programmable nuclease-based genome editing tool, the CRISPR/Cas9 system has been widely used in target-gene repair and gene-expression regulation. The DNA mutation generated by CRISPR/Cas9-mediated double-strand breaks determines its biological and phenotypic effects. Experiments have demonstrated that CRISPR/Cas9-generated cellular-repair outcomes depend on local sequence features. Therefore, the repair outcomes after DNA break can be predicted by sequences near the cleavage sites. However, existing prediction methods rely on manually constructed features or insufficiently detailed prediction labels. They cannot satisfy clinical-level-prediction accuracy, which limit the performance of these models to existing knowledge about CRISPR/Cas9 editing. We predict 557 repair labels of DNA, covering the vast majority of Cas9-generated mutational outcomes, and build a deep learning model called Apindel, to predict CRISPR/Cas9 editing outcomes. Apindel, automatically, trains the sequence features of DNA with the GloVe model, introduces location information through Positional Encoding (PE), and embeds the trained-word vector matrixes into a deep learning model, containing BiLSTM and the Attention mechanism. Apindel has better performance and more detailed prediction categories than the most advanced DNA-mutation-predicting models. It, also, reveals that nucleotides at different positions relative to the cleavage sites have different influences on CRISPR/Cas9 editing outcomes.
As the third generation gene editing technology, Crispr/Cas9 has a wide range of applications. The success of Crispr depends on the editing of the target gene via a functional complex of sgRNA and Cas9 proteins. Therefore, highly specific and high on-target cleavage efficiency sgRNA can make this process more accurate and efficient. Although there are already many sophisticated machine learning or deep learning models to predict the on-target cleavage efficiency of sgRNA, prediction accuracy remains to be improved. XGBoost is good at classification as the ensemble model could overcome the deficiency of a single classifier to classify, and we would like to improve the prediction efficiency for sgRNA on-target activity by introducing XGBoost into the model. We present a novel machine learning framework which combines a convolutional neural network (CNN) and XGBoost to predict sgRNA on-target knockout efficacy. Our framework, called CNN-XG, is mainly composed of two parts: a feature extractor CNN is used to automatically extract features from sequences and predictor XGBoost is applied to predict features extracted after convolution. Experiments on commonly used datasets show that CNN-XG performed significantly better than other existing frameworks in the predicted classification mode.
Background: Immune checkpoint inhibitor (ICI) therapy has significantly improved treatment outcomes for various cancers by enhancing T cell-mediated anti-tumor immune responses. However, accurately predicting patient response to ICI treatment remains a major challenge due to the risk of immune-related adverse events. Microsatellite instability (MSI), as an important molecular biomarker characterized by high mutation rates and abundant tumor neoantigen production, has been demonstrated to effectively predict clinical benefits from immunotherapy. In gastric adenocarcinoma (STAD) patients, approximately 22% exhibit the MSI subtype while the majority are microsatellite stable (MSS). This significant molecular heterogeneity underscores the urgent need to develop reliable predictive tools. Methods: To address this problem, we developed a multimodal deep learning model named ProMMF_Kron based on a multicenter dataset comprising 282 patients. The model employs a two stage feature fusion strategy: first extracting key features from both molecular profiles and pathological images through differential gene analysis and a pretrained deep convolutional neural network, respectively; then designing a sophisticated fusion architecture incorporating Kronecker product operations and back-projection modules to achieve efficient interaction between gene expression features and pathological image features. The dataset was partitioned into training, validation, and testing sets at a ratio of 6:2:2. Results: Experimental results demonstrate that the ProMMF_Kron model effectively distinguishes between MSI and MSS subtypes (MSI versus MSS) and exhibits competitive predictive performance on independent test datasets, achieving an AUC of 0.96 (95% CI: 0.89-1.00), outperforming traditional single-modality prediction models (3.2% AUC improvement) and other multimodal fusion approaches (4.3% AUC improvement). Further validation confirms the model’s excellent stability and generalization capability, maintaining high predictive accuracy on colorectal cancer (CRC) dataset. Discussion: Through bioinformatics analysis and feature visualization techniques, this study also reveals potential associations between key molecular biomarkers and critical immune regulatory pathways, providing a powerful decision-support tool for precision immunotherapy in gastric cancer with substantial clinical translation value and application prospects.